|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
Aveo (Barely) Passes Study With Kidney Cancer Drug, Stock Falls
|
Luke Timmerman |
01/03/12 |
Boston
|
|
Antigenics Expands Experimental Cancer Treatment, Novartis Adds to Cambridge Presence, Boston Scientific Sells Unit to Stryker, & More Boston-Area Life Sciences News
|
Erin Kutz |
10/29/10 |
Boston
|
|
Antigenics, and its UCSF Champion, Stick With Immune Booster For Brain Cancer
|
Luke Timmerman |
10/25/10 |
Boston
|
|
Aveo Pharma Stock Jumps 40 Percent in A Week, CEO Notes Progress in Pivotal Kidney Cancer Trial
|
Ryan McBride |
08/31/10 |
Boston
|
|
Aveo Pharmaceuticals Eyes $86.3M IPO
|
Ryan McBride |
12/17/09 |
Boston
|
|
Antigenics Shares Plummet as Cancer Vaccine Application Rejected in Europe
|
Luke Timmerman |
10/21/09 |
Boston
|
|
Aveo Pieces Together a Plan to Rival Big Boys of Cancer Drug World
|
Luke Timmerman |
06/29/09 |
Boston
|
|
ZymoGenetics Kidney Cancer Drug Shrinks, Stabilizes Tumors in Sickest Patients
|
Luke Timmerman |
05/31/09 |
Seattle
|
|
Aveo Kidney Cancer Drug, Challenging Pfizer and Bayer, Passes Important Test
|
Luke Timmerman |
05/29/09 |
Boston
|
|
ZymoGenetics Takes Back Full Rights to Cancer Drug Candidate
|
Luke Timmerman |
01/28/09 |
Seattle
|
|
Antigenics Asks European Regulators to Approve Oncophage for Kidney Cancer
|
Luke Timmerman |
10/22/08 |
Boston
|
|
Page 1 of
1 |
|
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.